SCF ENCYCLOPEDIA ENTRY

TUBEROUS SCLEROSIS COMPLEX (TSC)

SCF MTOR HYPERACTIVATION & CELLULAR GROWTH-SUPPRESSION FAILURE DOSSIER

I. OFFICIAL DISEASE CLASSIFICATION

Tuberous Sclerosis Complex belongs to SCF Clinical Domains C1 (Genomic Medicine), C7 (Neurobiology), C6 (Cellular Systems Biology), C14 (Developmental Biology), C13 (Oncology Biology), and C16 (Neurobehavioral Biology).

II. CLINICAL DEFINITION

Tuberous Sclerosis Complex is a multisystem genetic disorder characterized by:

• Benign tumor (hamartoma) formation
• Epilepsy
• Autism-spectrum manifestations
• Cognitive impairment
• Renal disease
• Dermatologic abnormalities

Primary affected systems:

• Brain
• Skin
• Kidneys
• Heart
• Lungs
• Eyes

Associated conditions:

• Epilepsy
• Autism Spectrum Disorder

III. MAJOR CLASSIFICATIONS

A. TSC1-Associated Disease

B. TSC2-Associated Disease

C. Mosaic TSC

IV. CORE SCF ETIOPATHOGENIC THESIS

Within the Synergistic Compatibility Framework (SCF), Tuberous Sclerosis represents a systems-level collapse of:

• Cellular growth harmonics
• Nutrient-sensing regulation
• Developmental signaling fidelity
• Neural network stabilization
• Organ architecture maintenance

SCF interprets TSC as a biologic growth-governor failure syndrome in which cellular expansion signals become chronically activated, leading to inappropriate tissue growth and network dysfunction.

V. MTOR BIOLOGICAL FOUNDATION

Normal mTOR Function

The mTOR pathway regulates:

• Cell growth
• Protein synthesis
• Autophagy
• Metabolism
• Tissue repair
• Development

Associated concept:

• Mechanistic Target of Rapamycin

Normal TSC Complex Function

TSC1 and TSC2 form a regulatory complex that suppresses excessive mTOR activity.

Normal relationship:

$TSC1/TSC2\Rightarrow mTOR\ Inhibition$

VI. MAJOR GENETIC CAUSES

Primary Genes

Inheritance:

VII. CORE PATHOPHYSIOLOGIC MECHANISMS

Disease pathway:

$TSC1/TSC2\ Loss\Rightarrow mTOR\ Hyperactivation$

VIII. SCF FAULT ARCHITECTURE

IX. MULTI-OMICS PATHOGENESIS

A. Genomics

Affected pathways:

• mTOR signaling
• Growth regulation
• Cell-cycle control
• Neural development

B. Transcriptomics

Dysregulated pathways:

• Protein synthesis
• Metabolic regulation
• Synaptic development
• Cellular proliferation

C. Proteomics

Observed abnormalities:

• mTOR pathway proteins
• Ribosomal proteins
• Growth regulators
• Synaptic proteins

D. Metabolomics

Key dysfunction:

• Nutrient-sensing abnormalities
• Excess anabolic signaling
• Reduced catabolism
• Autophagy suppression

E. Neurodevelopmental Omics

Observed abnormalities:

• Cortical organization defects
• Synaptic dysregulation
• Network hyperexcitability
• Connectivity disturbances

X. SCF PATHOGENESIS FLOW

Stage 1 — TSC Mutation

TSC1 or TSC2 becomes dysfunctional.

Stage 2 — mTOR Hyperactivation

Growth-regulation systems become dysregulated.

Stage 3 — Cellular Overgrowth

Abnormal proliferation develops.

Stage 4 — Hamartoma Formation

Organ-specific lesions emerge.

Stage 5 — Neural Network Dysfunction

Seizures and developmental abnormalities appear.

Stage 6 — Multisystem Disease

Progressive organ involvement develops.

XI. SYSTEMIC CONSEQUENCES

Associated conditions:

• Renal angiomyolipoma
• Lymphangioleiomyomatosis

XII. RHENOVA INTERPRETATION

Project RHENOVA interprets TSC as a biologic growth-controller lock-open syndrome.

RHENOVA Dynamics

• Excessive growth signaling
• Resource overconsumption
• Structural overdevelopment
• Network instability
• Organ-specific expansion

RHENOVA Biomarkers

XIII. DBI INTERPRETATION

The SCF Decentralized Biological Intelligence framework interprets tissues as distributed growth-regulation networks.

Normal functions:

• Growth limitation
• Resource allocation
• Structural maintenance
• Adaptive repair
• Signal integration

DBI Failure Features

• Runaway growth signaling
• Resource misallocation
• Localized expansion zones
• Communication instability

This transforms a balanced tissue-regulation system into a chronically activated growth state.

XIV. CLINICAL MANIFESTATIONS

Neurologic Manifestations

Common findings:

• Seizures
• Infantile spasms
• Intellectual disability
• Autism-spectrum features

Associated condition:

• Infantile spasms

Dermatologic Manifestations

Common findings:

• Hypomelanotic macules
• Facial angiofibromas
• Shagreen patches
• Ungual fibromas

Associated condition:

• Facial angiofibroma

Renal Manifestations

• Angiomyolipomas
• Renal cysts
• Renal dysfunction

Cardiac Manifestations

• Cardiac rhabdomyomas

Associated condition:

• Cardiac rhabdomyoma

XV. DIAGNOSTICS

Diagnostic Hallmarks

Genetic principle:

$TSC1/TSC2\ Mutation\Rightarrow mTOR\ Activation$

Biologic relationship:

$mTOR\ Hyperactivation\Rightarrow Cellular\ Overgrowth$

Clinical consequence:

$Growth\ Dysregulation\Rightarrow Hamartoma\ Formation$

XVI. STANDARD OF CARE

mTOR Inhibitor Therapy

Major targeted treatments:

• Everolimus
• Sirolimus

Neurologic Management

• Antiseizure medications
• EEG monitoring
• Epilepsy surgery (selected patients)

Associated therapy:

• Epilepsy surgery

Organ Surveillance

Routine monitoring includes:

• Brain imaging
• Renal imaging
• Cardiac evaluation
• Pulmonary assessment

XVII. SCF-PCR THERAPEUTIC ARCHITECTURE

A. Preventative (PCR-P)

Goals:

• Early diagnosis
• Genetic counseling
• Seizure prevention
• Organ surveillance

B. Curative (PCR-C)

Future goals:

• TSC gene correction
• Precision mTOR normalization
• Growth-regulation restoration

C. Restorative (PCR-R)

Goals:

• Preserve neurologic function
• Reduce lesion burden
• Restore network stability
• Re-establish growth-control synchronization

XVIII. ETHNOBIOPROSPECTING TARGETS

Note: No botanical intervention can replace proven mTOR-targeted therapies or correct TSC mutations. The following represent exploratory mTOR-modulating, neuroprotective, and autophagy-related research domains.

Traditional Chinese Medicine

• Scutellaria baicalensis
• Gastrodia elata

Ayurveda

• Withania somnifera
• Bacopa monnieri

Vietnamese Thuốc Nam

• Centella asiatica
• Polyscias fruticosa

XIX. SCF API DISCOVERY TARGETS

High-Priority Molecular Targets

1. TSC1 gene-replacement platforms
2. TSC2 gene-correction technologies
3. Precision mTOR-regulation therapeutics
4. Autophagy-restoration systems
5. Neural-network stabilization biologics
6. Hamartoma-growth suppression therapies
7. Cellular growth-synchronization restoration technologies

XX. SCF LAYMAN’S SUMMARY

Tuberous Sclerosis Complex is a genetic disorder caused by mutations in the TSC1 or TSC2 genes, which normally act as brakes on cellular growth through regulation of the mTOR pathway. When these genes fail, cells grow and divide excessively, forming benign tumors called hamartomas throughout the body. The brain is frequently affected, leading to epilepsy, developmental delays, autism-spectrum features, and cognitive challenges. SCF interprets TSC as a biologic growth-control failure syndrome in which the body’s internal growth-regulation system becomes chronically overactive, resulting in abnormal tissue expansion and neural-network instability.

XXI. STRATEGIC RESEARCH PRIORITIES

1. TSC1/TSC2 gene-repair therapies
2. Next-generation mTOR modulators
3. Autophagy-restoration platforms
4. Neural-network stabilization strategies
5. Precision seizure-prevention systems
6. Organ-specific growth-control therapeutics
7. Cellular growth-synchronization restoration technologies

MASTER REGISTRY INDEX

SCF-TSC-0001 — Tuberous Sclerosis Complex Master Registry

SCF-TSC-MTOR-0002 — mTOR Hyperactivation Layer

SCF-TSC-GROWTHCONTROL-0003 — Cellular Growth Suppression Failure Layer

SCF-TSC-HAMARTOMA-0004 — Benign Tumor Formation Layer

SCF-TSC-RHENOVA-0005 — Growth Controller Lock-Open Layer

SCF-TSC-DBI-0006 — Distributed Growth Regulation Failure Layer

SCF-TSC-PCR-0007 — Preventative–Curative–Restorative Layer